Volume 9, Number 1—January 2003
Perspective
Maintaining Fluoroquinolone Class Efficacy: Review of Influencing Factors
W. Michael Scheld*
Table 2
Comparison of pharmacokinetic and pharmacodynamic parameters for four fluoroquinolones and selected bacterial speciesa
| Streptococcus pneumoniae | Pseudomonas aeruginosa | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Fluoroquinolone |
Dose
(mg) |
Cmaxa,b
(mg/L) |
AUC24b
(mg x h/L) |
MICc |
Cmax:MIC |
AUIC |
MICc |
Cmax:MIC |
AUIC |
|
| Ciprofloxacin |
500 |
3.0 |
28 |
2 |
1.5 |
14 |
4 |
0.75 |
7 |
|
| 750 |
3.6 |
32 |
2 |
1.8 |
16 |
4 |
0.9 |
8 |
||
| Levofloxacin |
500 |
5.7 |
48 |
1 |
5.7 |
48 |
16 |
0.36 |
3 |
|
| Moxifloxacin |
400 |
4.5 |
48 |
0.25 |
18 |
192 |
8 |
0.56 |
6 |
|
| Gatifloxacin | 400 | 4.2 | 34 | 0.5 | 8.4 | 68 | 8 | 0.52 | 4.25 | |
